These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 26756205)

  • 1. Computational Trials: Unraveling Motility Phenotypes, Progression Patterns, and Treatment Options for Glioblastoma Multiforme.
    Raman F; Scribner E; Saut O; Wenger C; Colin T; Fathallah-Shaykh HM
    PLoS One; 2016; 11(1):e0146617. PubMed ID: 26756205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multilayer grow-or-go model for GBM: effects of invasive cells and anti-angiogenesis on growth.
    Saut O; Lagaert JB; Colin T; Fathallah-Shaykh HM
    Bull Math Biol; 2014 Sep; 76(9):2306-33. PubMed ID: 25149139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of avastin in the management of recurrent glioblastoma.
    Sweet JA; Feinberg ML; Sherman JH
    Neurosurg Clin N Am; 2012 Apr; 23(2):331-41, x. PubMed ID: 22440876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single Cell Mathematical Model Successfully Replicates Key Features of GBM: Go-Or-Grow Is Not Necessary.
    Scribner E; Fathallah-Shaykh HM
    PLoS One; 2017; 12(1):e0169434. PubMed ID: 28046101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pseudoprogression and treatment effect.
    Jahangiri A; Aghi MK
    Neurosurg Clin N Am; 2012 Apr; 23(2):277-87, viii-ix. PubMed ID: 22440871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Image-driven modeling of the proliferation and necrosis of glioblastoma multiforme.
    Patel V; Hathout L
    Theor Biol Med Model; 2017 May; 14(1):10. PubMed ID: 28464925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined targeting of PDK1 and EGFR triggers regression of glioblastoma by reversing the Warburg effect.
    Velpula KK; Bhasin A; Asuthkar S; Tsung AJ
    Cancer Res; 2013 Dec; 73(24):7277-89. PubMed ID: 24148623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recurrent glioblastoma multiforme: advances in treatment and promising drug candidates.
    Simpson L; Galanis E
    Expert Rev Anticancer Ther; 2006 Nov; 6(11):1593-607. PubMed ID: 17134364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Invasion as target for therapy of glioblastoma multiforme.
    Vehlow A; Cordes N
    Biochim Biophys Acta; 2013 Dec; 1836(2):236-44. PubMed ID: 23891970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiangiogenic therapies in glioblastoma multiforme.
    McNamara MG; Mason WP
    Expert Rev Anticancer Ther; 2012 May; 12(5):643-54. PubMed ID: 22594899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pleiotropic Chemotherapy to Abrogate Glioblastoma Multiforme Migration/Invasion.
    Helson L; Majeed M
    Anticancer Res; 2019 Jul; 39(7):3423-3427. PubMed ID: 31262865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 17AEP-GA, an HSP90 antagonist, is a potent inhibitor of glioblastoma cell proliferation, survival, migration and invasion.
    Miekus K; Kijowski J; Sekuła M; Majka M
    Oncol Rep; 2012 Nov; 28(5):1903-9. PubMed ID: 22941268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [GLIOBLASTOMA MULTIFORME--THE PROGRESS OF KNOWLEDGE ON THE PATHOGENESIS OF CANCER].
    Wańkowicz P; Nowacki P
    Ann Acad Med Stetin; 2014; 60(2):40-3. PubMed ID: 26591106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of antiangiogenic targeted toxins against glioblastoma multiforme.
    Hall WA; Vallera DA
    Neurosurg Focus; 2006 Apr; 20(4):E23. PubMed ID: 16709029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blockade of TGF-β signaling by the TGFβR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma.
    Zhang M; Kleber S; Röhrich M; Timke C; Han N; Tuettenberg J; Martin-Villalba A; Debus J; Peschke P; Wirkner U; Lahn M; Huber PE
    Cancer Res; 2011 Dec; 71(23):7155-67. PubMed ID: 22006998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The search for novel therapeutic strategies in the treatment of recurrent glioblastoma multiforme.
    Bambury RM; Morris PG
    Expert Rev Anticancer Ther; 2014 Aug; 14(8):955-64. PubMed ID: 24814143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of tumor p53 and PCNA with response and survival of glioblastoma in patients treated with an ECOG protocol of pre-irradiation chemotherapy.
    Grunnet ML; O'Neill A; Gilbert M; Hellman R
    Clin Neuropathol; 2000; 19(5):230-4. PubMed ID: 11048748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bevacizumab-based therapy in relapsed glioblastoma: rationale and clinical experience to date.
    Chinot OL
    Expert Rev Anticancer Ther; 2012 Nov; 12(11):1413-27. PubMed ID: 23249106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of anti-angiogenesis on glioblastoma growth and migration: model to clinical predictions.
    Scribner E; Saut O; Province P; Bag A; Colin T; Fathallah-Shaykh HM
    PLoS One; 2014; 9(12):e115018. PubMed ID: 25506702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recurrent glioblastoma: volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab.
    Huang RY; Rahman R; Hamdan A; Kane C; Chen C; Norden AD; Reardon DA; Mukundun S; Wen PY
    Cancer; 2013 Oct; 119(19):3479-88. PubMed ID: 23821555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.